Carprofen NEW
Price | $36 | $52 | $75 |
Package | 50mg | 100mg | 200mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: Carprofen | CAS No.: 53716-49-7 |
Purity: 99.65% | Supply Ability: 10g |
Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | Carprofen |
Description | Carprofen (Ridamyl) is a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities. |
In vitro | Administration of 4 mg/kg Carprofen significantly elevated peak plasma concentrations in dogs. Compared to buprenorphine, Carprofen treatment resulted in marginally superior analgesic effects with reduced sedative action in canines. Preoperative administration of Carprofen in dogs yielded lower pain scores than other groups, with marked effectiveness observed 2 hours post-extubation. Carprofen provided sustained analgesia for 18 hours in treated canines without adverse side effects and notably improved the speed of recovery in limping birds. |
In vivo | Carprofen binds to human serum albumin (HSA) via fluorescence and equilibrium dialysis methods, with two sets of binding constants [K1=5.1 μM (fluorescence) and 3.7 μM (ED), K2=37 μM (fluorescence) and 13 μM (ED)]. It predominantly binds to site II, the benzodiazepine site, while site I, the Warfarin site, exhibits a lower affinity for Carprofen. The carboxyl group of Carprofen plays a significant role in its high-affinity binding with HSA. Additionally, Carprofen (S and R enantiomers) inhibits canine COX2 with an IC50 of 0.102 microM, primarily attributed to the S enantiomer (IC50, 0.0371 μM), which is approximately 200 times more potent than the R enantiomer (IC50, 5.97 microM). |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : 51 mg/mL (186.3 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 55 mg/mL (200.94 mM) |
Keywords | FAAH | Autophagy | Inhibitor | Cyclooxygenase | Carprofen | COX | Fatty acid amide hydrolase | inhibit |
Inhibitors Related | Hydroxychloroquine | Guanidine hydrochloride |
Related Compound Libraries | Pain-Related Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$36.00/50mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
$10.00/1KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-11-19 | |
$0.00/1kg |
VIP1Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-04-03 | |
$10.00/1kg |
Nantong Guangyuan Chemicl Co,Ltd
|
2023-10-12 | ||
$30.00/1kg |
Anhui Ruihan Technology Co., Ltd
|
2023-09-07 | ||
$0.00/25kg |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2023-08-14 | |
$1.00/1000KG |
VIP3Y
|
Zibo Shiji Zhonglian Medical Technology Co., Ltd.
|
2023-08-08 | |
$15.00/1KG |
Xiamen Wonderful Bio Technology Co., Ltd.
|
2023-07-21 | ||
$0.00/1kg |
Hpets Biotech Company (Chongqing) Co.,ltd
|
2023-03-21 | ||
$10.00/1KG |
Weijer International Trade (Hebei) Co., Ltd
|
2023-03-07 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY